Do not stop or change your medication without speaking to a pharmacist or healthcare professional.
Permanently Discontinued

OPTIMARK

LIEBEL-FLARSHEIM CANADA INC

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is OPTIMARK discontinued in Canada?

Yes. The manufacturer has reported to Health Canada that OPTIMARK 330.9MG has been permanently discontinued (last updated March 28, 2018). It is not expected to come back, so talk to your pharmacist or doctor about an alternative.

Why is OPTIMARK not available?

The reason the manufacturer reported: Business reasons.

Can I still get this?Possibly — same-ingredient product records found
StatusPermanently Discontinued
Same-ingredient products on file1 product
Affected strength330.9MG
Last updated2018-03-28

Other Products Containing the Same Active Ingredient

These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.

Closest Matches

OPTIMARK

LIEBEL-FLARSHEIM CANADA INC

330.9MG · DIN 02393174

Same strengthSame dosage formSame routeNo current shortage

What this means

Does this mean I need to switch medications right away?

Not necessarily right away, but this product will not be returning to the market.

What should I do?

Talk to your pharmacist or prescriber about your options well before your current supply runs out.

DIN

02242986

Strength

330.9MG

Dosage Form

SOLUTION

Route

INTRAVENOUS

Active Ingredient

GADOVERSETAMIDE

Tier

Unrated

Last Updated

2018-03-28

Reason for Shortage

Business reasons

Other Products from LIEBEL-FLARSHEIM CANADA INC

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.